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ABSTRACT 29 
Cereal-based products, like breads, are a vehicle for bioactive compounds, including polyphenols. The health 30 
effects of polyphenols like phenolic acids (PAs) are dependent on their bioaccessibility and bioavailability. 31 
The present review summarizes the current understanding of potential strategies to improve phenolic 32 
bioaccessibility and bioavailability and the main findings of in vitro and in vivo studies investigating these 33 
strategies applied to breads, including the use of raw ingredients with greater phenolic content and different 34 
pre-processing technologies, such as fermentation and enzymatic treatment of ingredients. There is 35 
considerable variability between in vitro studies mainly resulting from the use of different methodologies, 36 
highlighting the need for standardization. Of the few in vivo bioavailability studies identified, acute, single-37 
dose studies demonstrate that modifications to selected raw materials and bioprocessing of bran could 38 
increase the bioavailability, but not necessarily net content, of bread phenolics. The two medium term 39 
identified dietary interventions also demonstrated greater phenolic content resulting from modification of 40 
raw materials used. Overall, findings suggest that several strategies can be used to develop new bread 41 
products with greater phenolic bioaccessibility and bioavailability. However, due to the large variability and 42 
the few studies available, further investigations are required to better determine the usefulness of these 43 
innovative processes. 44 
 45 
KEYWORDS: bread, bioaccessibility, bioavailability, phenolic compounds. 46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
Page 4 of 47Food & Function
3 
 
 57 
INTRODUCTION 58 
Cereal-based products are the most common staple foods globally. Among the wide range of products, bread 59 
is one of the most consumed. The estimated bread consumption has been reported to be over 100 g per day 60 
(equivalent to approximately 3 slices per day) in many countries1–3, therefore bread is an important 61 
contributor to daily energy intake4. 62 
Bread products differ widely in shape, size, texture, and sensory characteristics. Part of these differences are 63 
ascribable to the type of cereal used for bread-making, which can include rye, barley, oat, and wheat, the 64 
latter of which is the most commonly used due to its gluten content, which contributes to good sensory 65 
characteristics. Differences can also result from the addition of ingredients, such as seeds, olives and nuts, as 66 
well as differences in the bread-making process, such as temperature and the use of yeast versus sourdough. 67 
Regardless of these differences, bread is generally characterized by a high carbohydrate and protein content, 68 
but it is also a rich source of vitamins (mainly from the B-vitamin group) and minerals (such as iron, 69 
calcium, phosphorus, zinc, potassium, and magnesium). 70 
Many bread products are also a good source of bioactive compounds, including fibre and other 71 
phytochemicals, specifically those made with wholegrains that consist of the intact, ground, cracked or 72 
flaked kernel after the removal of inedible parts such as the hull and husk. Only in wholegrain products are 73 
the principal anatomical components, including the starchy endosperm, germ and bran, present in the same 74 
relative proportions as in the intact kernel5. In the outer layers of the kernels, where the bran is found, there is 75 
a high content of bioactive compounds6.  76 
The consumption of whole grains has been associated with the prevention of chronic diseases, including 77 
cardiovascular disease and diabetes7,8. Therefore, clinical practice guidelines and dietary guidelines 78 
recommend choosing wholegrain products9–12, which are rich in bioactive compounds, over refined products, 79 
in which bioactive compounds are present only in small amounts due to the removal of the seed external 80 
layers during milling. 81 
Wholegrain bread products are rich in fibre, particularly insoluble fibre, for which bran represents one of the 82 
main sources. Fibre from bread products mainly includes arabinoxylans, a hemicellulose found in plant cell 83 
walls and that represent the major component of dietary fibre in cereal grains. The wheat grain also contains 84 
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aleurone as a monolayer of cells overlying the endosperm, which is rich in fibre and phenolic compounds. 85 
Furthermore, breads can be also rich in soluble fibres, like those made with oat and barley as good sources of 86 
β-glucans, which are well known to reduce post-prandial blood glucose and blood cholesterol13–15, risk 87 
factors in the development of coronary heart disease (CHD)16.  88 
Similarly to other cereal-based products, wholemeal bread is generally a good source of phenolic 89 
compounds, mainly as esters bound to arabinoxylans17, with a minor contribution of soluble free or 90 
conjugated compounds18. Polyphenols exist as secondary metabolites in several different plants, in which 91 
they can act as a defence mechanism against parasites and toxic compounds19,20. Phenolic compounds are 92 
widely diffused in all plant foods including fruits, vegetables and beverages (tea and coffee), the 93 
consumption of which may lead to a phenolic intake of ~1000 mg per day, in a typical American diet21. 94 
Bread products contribute to this daily phenolic intake, especially when they include bran.  95 
Cereal grains constitute a good source of phenolic acids (PAs), in addition to alkylresorcinols and lignans. 96 
PAs can be divided in two groups, hydroxycinnamic and hydroxybenzoic acids, deriving from the 97 
hydroxylation of the cinnamic or benzoic acid moiety. Hydroxycinnamic acids are the most abundant PAs 98 
and chiefly consist of ferulic acid (FA), p-coumaric acid (CA), caffeic acid, and sinapic acid (SA). 99 
Hydroxybenzoic acid derivatives include p-hydroxybenzoic, protocatechuic, vanillic, syringic and gallic 100 
acids.  101 
Polyphenols are not included in the category of micronutrients, as they are not essential for the maintenance 102 
of vital functions. However, several studies indicate that phenolic compounds might be responsible for part 103 
of the beneficial effects associated with the consumption of plant-based foods, such as the association 104 
between fruit and vegetable intake and reduced CVD risk 22. In particular, in vitro studies have demonstrated 105 
the involvement of polyphenols and their metabolites in several features linked to prevention of 106 
inflammation, oxidative stress and many other recognised pathophysiological processes 23–25. Furthermore, 107 
over the past 20 years, epidemiological studies have demonstrated that the consumption of polyphenol-rich 108 
foods, such as fruits, vegetables, cereals, coffee and cocoa, is inversely associated with the risk of many 109 
chronic diseases. The first epidemiological study focusing on the protective role of polyphenols on CHD 110 
found a 42% reduction in relative risk of CHD mortality when comparing the highest tertile of flavonoid 111 
intake to the lowest26. Several other epidemiological studies followed, including the Iowa Women’s Health 112 
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Study (n= 41,836), in which polyphenol intake was inversely associated with inflammation27, and 113 
specifically, whole grain polyphenol intake was inversely associated with the incidence of colorectal 114 
cancer28. 115 
Evidence from human intervention trials on the protective effects of phenol-rich foods against many chronic 116 
diseases has been inconsistent, possibly because of differences in food composition, as well as differences in 117 
the absorption and metabolism of various phenolic compounds. One of the main issues contributing to the 118 
inconsistency in results concerns studies attributing the effects to a single compound or a class of foods, 119 
because a single compound can be present in several different foods, and a class of foods can contain 120 
mixtures of polyphenols. In addition, the in vivo effects of polyphenols are strongly influenced by their 121 
bioavailability.  122 
Generally, bioavailability is the fraction of an ingested nutrient or compound that reaches the systemic 123 
circulation and may be utilized. Thus, it is multifactorial in that it includes gastrointestinal digestion, 124 
absorption, metabolism, tissue distribution, and bioactivity of the nutrient/compound. However, due to the 125 
difficulty in investigating the bioactivity, bioavailability is commonly considered both the fraction of a 126 
compound as well as the metabolite(s) of that compound that reach the systemic circulation29.  127 
Bioavailability can be affected by a wide range of factors, not only related to the food (e.g. chemical form of 128 
the compound, characteristics of the food matrix), but also to the individual (e.g. gastric emptying, intestinal 129 
transit time), resulting in high inter-individual variability24,30. 130 
Beginning with ingestion and digestion of a food, the food matrix can influence the bioaccessibility of the 131 
phenols because the amount that is released from within the matrix will influence the fraction that is made 132 
available for intestinal absorption. Effects on bioaccessibility can be evaluated in vitro by simulation of 133 
gastric and small intestinal digestion31. In vitro methods are quick and inexpensive ways to estimate the 134 
bioaccessibility of a bioactive compound, including changes resulting from variations in the food matrix and 135 
food processing. However, these methods cannot completely measure of the bioavailability of bioactives, as 136 
this requires in vivo methodologies. 137 
The present review summarizes potential strategies, including innovative technologies, that can be applied 138 
during the bread-making process in an effort to increase the fraction of phenolic compounds reaching the 139 
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systemic circulation, and what is currently known about the usefulness of these strategies as assessed in in 140 
vitro bioaccessibility and in vivo bioavailability studies. 141 
 142 
POTENTIAL STRATEGIES TO INCREASE PHENOLIC CONTENT IN BREAD PRODUCTS: 143 
EFFECTS OF THE BREAD-MAKING PROCESS  144 
Various processing techniques are applied to grains in order to transform the raw materials into finished 145 
products with good sensory characteristics and nutritional quality. Since technological processes affect the 146 
chemical constituents and physical properties of foods, it is expected they also influence the phenolics within 147 
grain products, thus impacting the potential beneficial health effects. The effect of various food-processing 148 
methods on phenolic compounds has therefore become an important area of research.  149 
A review of the literature has highlighted three main strategies that can be applied to design phenolic-150 
enriched breads: the first approach focuses on the use of raw materials naturally rich in phenolic compounds; 151 
the second focuses on the application of bio-processing techniques on raw materials; and the third focuses on 152 
the processing conditions that can be applied during bread-making (Table 1).  153 
Raw materials  154 
Whole grains are a good source of phenolic compounds, mostly concentrated in the bran, but levels of 155 
phenolics in the final products can vary widely depending on the raw materials and on the pre-processing 156 
techniques. In addition to whole wheat, barley, and rye, minor cereals (e.g. sorghum, millets;32), pigmented 157 
grains33–35, and ancient grains (e.g. eikorn, emmer36 and pseudocereals like buckwheat, quinoa and 158 
amaranth)37 represent a good source of phenolics, thus their use in bread products has increased in the 159 
marketplace. Since phenolic compounds are present in the external layers of the kernel, adding bran fractions 160 
to refined flour is one of the most common trends to enhance phenolic content in bread products.  161 
Pre-processing techniques 162 
Besides using wheat bran and whole-grain flour, several modifications to pre-processing techniques can be 163 
used to influence phenolic content in bread products. A variety of fractionation methods, including both wet 164 
extraction and dry fractionation, have been developed for producing milling fractions that are concentrated in 165 
phenolic compounds. Among fractionation methods, debranning (also named pearling) is the most widely 166 
used. It has been traditionally used as a tool to enhance both hygienic and technological performances of 167 
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milled flours38,39. More recently, debranning has been demonstrated as an effective strategy to produce bran 168 
fractions rich in aleurone particles40, which are particularly rich in phenolics, thus recovering the bioactive 169 
compounds that are concentrated in the external layers of grain kernels41–43.  170 
Regarding to physical treatments, air classification technology is an effective way to separate grain flours 171 
into fractions with different sizes, properties, and chemical composition, such as protein, starch, and dietary 172 
fibre. When applied to phenolic-rich material, it is a good technique to select fractions with a high content of 173 
phenolic compounds44.  174 
Micronization, also known as ultrafine grinding, is a mechanical treatment, used to change or damage the 175 
fibre matrix, causing some phenolics which were linked or embedded into the matrix to be exposed so that 176 
the total phenolic content in bran increases45 , likely due to an increase in extractability. 177 
Lastly, biotechnological processes (i.e. germination, fermentation, and enzymatic treatments) have been used 178 
to improve the PA content in bran. Germination is the process by which a plant grows from a seed. During 179 
germination, high levels of hydrolytic enzymes, such as amylases and proteases, accumulate in the cereal 180 
seed, so that the insoluble endosperm starch and protein reserves are hydrolyzed into soluble forms that can 181 
be transported to the embryo to meet the needs of the growing plant. A recent review on the effects of grain 182 
germination concluded that during this process a net increase in total phenolic content and total antioxidant 183 
capacity46 is observed. It is also thought that germination may increase the extractability of polyphenolic 184 
compounds, by releasing bound polyphenols, therefore making them more soluble in extraction solvents.  185 
Fermentation is another beneficial pre-processing technique which effectively releases phenolics from the 186 
bran of various grains47,48. The enzymes produced by the added microorganisms have the potential to release 187 
insoluble bound PAs from bran and thereby improve their bioaccessibility and potential bioavailability49. In 188 
the case of sourdough fermentation, the effect of the reduction in pH is also important50,51. The lower pH 189 
during sourdough fermentation favors the activity of hydrolases and can contribute to chemical disintegration 190 
of arabinoxylans, and to extensive hydrolysis of both esters and glycosides of PAs50,51. 191 
Combining fermentation with germination results in an additive effect, since germination results in a higher 192 
amount of fermentable sources (sugars and nitrogen) and both increase the concentration of cell wall 193 
degrading enzymes, all contributing to increased bioaccessibility of PAs47. 194 
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A third biotechnological process which can be applied during pre-processing is enzymatic treatment, 195 
whereby grains or bran are pre-treated with enzymes in a liquid environment. Enzymatic treatment has been 196 
reported to free PAs from fibre esters52, improving the bioavailability of these compounds53. Enzymes (e.g. 197 
xylanases) are also commonly used in the baking industry, as part of dough conditioners, to improve dough 198 
property, baking quality, and shelf-life54. 199 
Bread-making process 200 
In addition to the formulation and pre-processing of bread products, the bread-making process also 201 
influences the content and bioavailability of phenolic compounds in the final bread product. 202 
Bread-making includes several fundamental operations, namely mixing and kneading, fermentation or 203 
leavening, and baking, which are indispensable for producing an attractive end product. During mixing, 204 
ingredients are evenly distributed and blended. In wheat breads, interaction with water leads to significant 205 
structural changes in proteins, resulting in gluten formation; a three-dimensional network structure resulting 206 
in a cohesive, completely homogenous, non-sticky mass with well-defined rheological characteristics. These 207 
attractive properties depend on the procedure applied and equipment used, as well as on the presence of 208 
components, such as phenolics, that may negatively affect gluten viscoelasticity. For example, phenolic 209 
compounds can form complexes with proteins, via hydrogen bonding between the hydroxyl groups of the 210 
phenols and the carbonyl group of the peptide residue55–57.  211 
Studies have demonstrated that dough mixing causes an overall decrease in total PAs, such as bound FA, SA 212 
and CA, in various grains50,58,59 reaching up to 50%. However, free FA has been demonstrated to increase 213 
significantly in one study showing up to five times the initial level, suggesting that mixing may also facilitate 214 
the release of bound phenolic compounds into free and more bioaccessible forms35,58.  215 
Various mechanisms have been proposed to explain the overall decrease in PAs resulting from dough 216 
mixing. High-speed mixing breaks protein disulfide bonds and creates thiol free radicals in gluten, which 217 
then react with reducing compounds, like PAs, in flour60. Considering the proposed effect of mixing on the 218 
formation of bonds between phenolics and proteins, a decrease in phenolic content in various reports may be 219 
more accurately described as a reduction in their bioaccessibility and thus extractability61. 220 
Another proposed effect of mixing on phenolics is the hydrolysis of oxidative enzymes such as oxygenase 221 
and peroxidase, that are present in flours, which become active when water is added and thus decrease the 222 
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amount of phenolics like FA62.  223 
The leavening and fermentation process increases the original volume of the bread and creates a porous 224 
structure, through the action of a leavening agent, usually baker’s yeast (i.e. Saccharomyces cerevisiae), 225 
which converts the fermentable sugars present in the dough into ethanol and CO2.  226 
The fermentation and leavening process may contribute to an increase in PA bioavailability. Two 227 
mechanisms for the fermentation-induced increase in bioaccessibility and bioavailability of phenolic 228 
compounds during bread-making have been proposed: i) via the structural breakdown of the cell wall matrix 229 
by degrading enzymes present in both grains and microbes activated by the leavening agent63; and ii) via the 230 
synthesis or enzymatic transformation of various bioactive compounds47. However, studies investigating PA 231 
content in fermented dough are not consistent. This inconsistency is likely due to differences in the enzymes 232 
produced from yeast or other microorganisms and native enzymes present in various types of grains. As an 233 
example, rye has been described to have much more native enzymatic activity compared to wheat35,50,51,59. In 234 
addition, fermentation conditions, particularly temperature, pH, and duration, are contributing factors to PA 235 
content. With regards to the fermentation time, prolonged fermentation increases the number of bonds 236 
broken between PAs and dietary fibre, thus increasing the bioaccessibility of PAs35.  237 
The type of fermentation also influences PA content. An alternative to the use of dry yeast is the use of 238 
sourdough. Leavening with sourdough consists in the use of a starter, represented by a piece of dough from a 239 
previous batch, which is fermented and stored under controlled conditions of temperature and humidity. The 240 
intense acidification markedly influences the sensory and shelf-life features of the baked goods. With 241 
sourdough, dough acidification and leavening capability is determined by the interactions between lactic acid 242 
bacteria and yeasts. This kind of fermentation has a well-established role in improving flavor, structure, and 243 
shelf-life of rye and wheat breads.  244 
Sourdough fermentation has been demonstrated to increase the bioaccessibility of PAs as, for example, 245 
Liukkonen et al. (2003)64 found that this type of fermentation increased the content of methanol-extracted 246 
phenolic compounds, in addition to demonstrating an increase in antioxidant capacity43,60. As mentioned 247 
above, low pH favors the hydrolysis of both esters and glycosides of PAs50,51. However, different lactic acid 248 
bacteria strains exhibit varying abilities in enhancing the extraction of free phenolics, with, for example, the 249 
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maximum increase in FA - in whole grain barley and oat groat when Lactobacillus johnsonii LA1, 250 
Lactobacillus reuteri SD2112, and Lactobacillus acidophilus LA-5 were used65.  251 
Lastly, baking is considered the most important stage of the bread-making process. During baking, the 252 
exchange of heat (as the dough heats up) and material (as the dough loses water/humidity) causes physical, 253 
chemical and biochemical changes resulting in the transition from foam to sponge state and the 254 
diversification between crust and crumb.  255 
It is assumed that antioxidants, including PAs, contained in grains are lost during thermal treatments, due to 256 
degradation, oxidative condensation, or decomposition of thermolabile phenolics caused by high 257 
temperature66,67. However, the most recent research has reported that baking increases the total PA and FA 258 
levels35,59,68, likely due to the intense heat that makes PAs more bioaccessible. Yu and Beta (2015)35 found 259 
higher contents of soluble FA and p-hydroxybenzoic acids in bread crumb compared to crust, suggesting that 260 
some free PAs are thermally labile (since there is a higher, more intense heat in bread crust). However, 261 
higher levels of insoluble PAs can be found in the crust35,59,68. Heat stress could cause degradation of 262 
conjugated polyphenolic compounds resulting in an increase in free PAs, which has been demonstrated in 263 
wheat53. This would improve bioavailability of phenolic compounds since it is believed that free PAs are 264 
more readily available than bound PAs69. The effect of baking temperature on free or bound PAs can vary 265 
due to the nature and source of phenolic compounds as well as the baking method (e.g. yeast vs. 266 
sourdough)51,70.  267 
 Unlike temperature, baking time does not seem to affect total PA content of wholegrain bread, as 268 
demonstrated in one study comparing breads baked at 10, 20 or 35 minutes68. Additionally, Maillard reaction 269 
that occurs during baking may contribute to the formation of new phenolic structures68,71. Angioloni and 270 
Collar (2011)72 demonstrated that some PAs, such as protocatechuic, syringic, SA and FA, were detected in 271 
bread but not in the raw flour. This has also been shown in studies conducted with bread made from 272 
pigmented wheat35 and rye whole meal50.  273 
Furthermore, one study demonstrated that although there is a measurable decrease in total PA and FA 274 
content that occurs during dough preparation, their concentrations significantly increased after baking to 275 
levels that surpassed those measured prior to dough preparation59. The baking process, however can have 276 
different effects depending on the type of grain used. For example, in breads made with pseudocereals (e.g. 277 
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amaranth, quinoa, and buckwheat), polyphenol content has generally been found to be reduced in the final 278 
bread product when compared to the original grains66,67. 279 
 280 
BIOACCESSIBILITY OF PHENOLIC COMPOUNDS IN BREAD: In vitro studies 281 
Methods of assessment of bioaccessibility: Static vs. Dynamic Methods 282 
Bioaccessibility is the determination of the amount of bioactive compounds potentially absorbable from the 283 
gut lumen, and can be measured using different methods which simulate in vivo digestion. Several in vitro 284 
methods have been developed to investigate the effect of the food matrix and of different processing 285 
techniques on the ability of nutrients or bioactive compounds, like polyphenols, to become available to 286 
absorbtion73. These methods try to mimic in vivo digestion by simulating the oral, gastric and small intestinal 287 
phases and, occasionally, large intestinal fermentation74. 288 
There are two general categories of methods: static and dynamic (non-static). In static models, products 289 
remain largely immobile in a single bioreactor, and the ratios between meal, enzymes, salt, bile acids and all 290 
other substrates of the biological digestive reactions are kept constant at each phase of digestion. Static 291 
methods can differ in incubation time and characteristics of the digestive juices, namely the concentrations of 292 
the enzymes resulting from the preparation, for example by the addition of specific enzymes to inorganic and 293 
organic solutions. They can be also adjusted for pH on the basis of the specific gut compartment, as static 294 
methods consist of multiple phases, including oral, gastric and intestinal, each of which can vary slightly in 295 
different studies. 296 
In the oral phase, the incubation time of the test sample can vary between 2 and 30 minutes74,75 with either: i) 297 
human buffered saliva with phosphate or saline solution74; ii) α-amylase solution75,76; or iii) saliva solution 298 
prepared with different salts and with the addition of α-amylase, uric acid and mucin77. Some studies bypass 299 
the oral phase72,78 possibly because a significant contribution to the digestive process is not expected in this 300 
stage due to the short time during which food is in contact with saliva in in vivo conditions79.  301 
In the gastric phase, a pepsin solution is normally used and incubation time can vary between 1 and 2 302 
hours72,74–78. The addition of mucin has also been reported77. Furthermore, hydrochloric acid is commonly 303 
used to more accurately simulate in vivo gastric conditions79.  304 
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In the intestinal phase, neutralization as well as incubation with pancreatic enzymes is set up. The enzymes 305 
used in most studies include pancreatin74, a bile/pancreatin solution72,76,78, or a duodenal juice including 306 
pancreatin, lipase and bile77. Incubation time can vary from 2 to over 24 hours74,76,77. 307 
After gastrointestinal digestion simulation, the point at which bioaccessibility determination of compounds 308 
of interest occurs can also vary. One method is to centrifuge or filtrate the sample mixture to measure the 309 
bioaccessibility of compounds based on the levels present in the supernatant. An alternative method includes 310 
the use of a dialysis membranes, which allows for the discrimination between high and low molecular weight 311 
components31. When a dialysis tube is used, the undigested material (the fraction remaining inside the tube) 312 
can be analysed for the content of the nutrient/bioactive compound under study (e.g. PAs) and then the 313 
bioaccessibility can be obtained as a difference from that measured in the sample before digestion74,76. The 314 
time at which the dialysis tube is used may vary, as in some works it is used immediately after the gastric 315 
phase74 while in others after the intestinal digestion phase76. 316 
In general, static methods are quick, cost-effective and can be used to assess effects on several nutrients and 317 
bioactive compounds resulting from changes made to the food matrix, by changing the raw materials or 318 
processing techniques used, compared to the reference material or to the original food matrix. 319 
The main limitations of static methods are that they do not provide the most accurate simulation of the 320 
complex dynamic physiological processes occurring during in vivo conditions. This has led to the 321 
development of dynamic (non-static) digestion models. A common and very sophisticated gut model to 322 
simulate the human digestive system was developed by The Netherland Organization for Applied Scientific 323 
Research80. Their commercial gastrointestinal model, also known as the TIM system, is a multi-324 
compartmental dynamic computer-controlled model that has been successfully used to study the 325 
bioaccessibility of many compounds including vitamins and minerals, as well as phenolics81,82. The TIM 326 
system simulates the dynamic conditions occurring in the four main gastrointestinal compartments: stomach, 327 
duodenum, jejunum and ileum. All parameters, including gastric and small intestinal transit, flow rate, 328 
composition of digestive fluids, temperature, pH, and removal of water and metabolites, are all remote-329 
computer controlled. In the jejunal and ileal compartments, a dialysis system allows for the removal of 330 
digestion products, isolating the dialysate fraction, which contains the bioaccessible products from the 331 
“unabsorbed” sample.  332 
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Overall, the use of realistic concentrations of digestive enzymes, pH levels, transit times appropriate to each 333 
digestion step, and salt concentrations, among other factors, contribute to a more accurate simulation of the 334 
gastrointestinal tract. Furthermore, the removal of the products of digestion and the appropriate mixing at 335 
each stage of digestion in the use of dynamic methods may represent crucial points in mimicking 336 
physiological conditions in vivo. 337 
In vitro studies investigating effects of altering raw materials on phenolic bioaccessibility 338 
Table 2 shows the main findings of all studies identified in the literature and evaluating the bioaccessibility 339 
of phenolic compounds in bread. Among the different potential strategies to apply in the bread-making 340 
process to increase the bioaccessibility of phenolic compounds in breads, as summarized in Table 1, the 341 
efficacy of using different raw materials has been the most investigated. In particular, the majority of the 342 
studies has explored the bioaccessibility in breads made by using different types of cereals or pseudocereals. 343 
As expected, wheat-based breads (both white and wholegrain) were the most investigated (in all 9 studies), 344 
with few investigating rye (2/9), oat (1/9) and barley (1/9), either alone or mixed. Among pseudocereals, 345 
buckwheat breads were analysed in two out of the nine studies.  346 
Almost all studies included wheat bread as an internal control to be compared with breads made with 347 
different cereals. Generally, white bread is characterized by a low bioaccessibility of PAs, partially 348 
ascribable to the very low FA content in the samples83, especially in its free form. Three studies, investigated 349 
the bioaccessibility of PAs in white breads following digestion by the dynamic TIM system, expressing 350 
results as the percentage of PAs in the dialysate in relation to the original sample69,83,84. In the first study by 351 
Mateo Anson et al. (2009 a)69, FA was undetected in the dialysate-samples, whereas in the second study, 352 
conducted by the same authors84, 4.9% FA bioaccessibility was reported. CA and SA were measured in the 353 
second study84, but they were not detected in the dialysate, post-digestion. The third study by Hemery and 354 
colleagues (2010)83 found a 10.2% FA bioaccessibility.  355 
In another study conducted by Angioloni and Collar (2011)72, the authors found a 58% bioaccessibility of the 356 
total phenolics (measured as Total Phenolic Content, TPC) in the supernatant from static in vitro digestion of 357 
wheat bread. This is similar to a second study conducted by the same authors, in which they found ~84% 358 
TPC bioaccessibility in wheat bread, although in this latter study the percentage bioaccessibility was 359 
calculated from the initial TPC in flour as opposed to the bread, as is typically done78.  360 
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The differences in bioaccessibility in white wheat bread found in the latter two studies (58% and 84% for 361 
TPC) compared to the former three studies (0% FA, 4.9% FA and 10.2% FA) may be linked to the former 362 
three measuring FA only, using chromatographic methods, while the latter two measured total phenolics 363 
using the Folin-Ciocalteau method. In addition to potential differences due to type of in vitro method (i.e. 364 
static vs. dynamic), further sources of variability might include the phenolic content in the raw materials, as 365 
well as the state of the test samples used for post- digestion measurements (i.e. dialysate samples in former 3 366 
versus supernatant and precipitate used in the latter 2 studies).  367 
Three studies compared the bioaccessibility of phenolic compounds in white bread with respect to whole 368 
wheat bread69,75,83. As expected, the whole wheat breads had higher initial PA content, due to the 369 
preservation of the outer layers of the kernels (e.g. 9-12-fold higher FA content in whole wheat versus white 370 
bread). This contributed to a greater net content of bioaccessible PAs, demonstrating how the use of different 371 
raw materials is a valid strategy for this purpose. However, although the net content of bioaccessible PAs in 372 
whole wheat bread is higher than that of white bread, the bioaccessibility was higher in white breads 373 
compared to whole wheat (e.g. 4.9% versus 1.1% in Mateo Anson et al. (2009b)84 and 10.2% FA vs. 2.9% 374 
FA in Hemery et al. (2010)83). Nevertheless, other studies have observed much higher bioaccessibility for 375 
specific PA in whole wheat breads. For example, Dall’Asta, et al. (2016)74 found a 13.1% FA 376 
bioaccessibility in whole grain bread, but this may be due to differences in the methods used, with this latter 377 
study using a static digestion model. Variations in bioaccessibility in whole wheat breads may also differ due 378 
to the type of whole wheat or whole grain bread used, as the former two studies produced breads from flour 379 
at lab level, while the latter used a commercial whole grain bread which may have been exposed to different, 380 
perhaps greater, degrees of processing. Furthermore, there seem to be no differences in bioaccessibility for 381 
different types of PA. For example, FA appears to have lower percentage bioaccessibility compared to CA 382 
and SA, regardless of the analytical method74,83. This may be due to different distributions of phenolic 383 
compounds in the free, conjugated, and bound forms.  384 
Szawara-Nowak and colleagues (2016)75, following in vitro digestion of white wheat bread, found a soluble 385 
fraction of these compounds quite comparable to the content in dark wheat bread (∼9 mg rutin equivalent/g 386 
dry weight). They reported, for both white and dark bread, an exceptionally large increase in rutin post 387 
versus pre-digestion (∼20 and ∼9 fold, respectively), which is much greater compared to any other study. 388 
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Similar unexpected increases following digestion were also found with increasing substitution of buckwheat 389 
flour (both white and roasted) in white and dark breads75. Authors hypothesized this may be due to an 390 
increase in the extractability of phenolic compounds resulting from the parameters set in their in vitro 391 
digestion, including pH, temperature, incubation times, and extraction solvent.  392 
As reported in Table 1, a strategy to increase PA content in bread includes modifications to the raw 393 
materials. The use of different types of cereals or pseudocereals, or a mixture of them, is a strategy to 394 
increase PA content which has become increasingly common85. In the above-mentioned study, Angioloni 395 
and Collar (2011)72 assessed the differences in TPC in breads made with oat, rye, buckwheat and wheat 396 
flours. Among the four breads made with 100% of one single type of flour, the TPC (measured by Folin-397 
Ciocalteau method) in the initial bread was highest in buckwheat (808 mg GAE/kg), followed by wheat (685 398 
mg GAE/kg), oat (643 mg GAE/kg) and rye (536 mg GAE/kg). Following in vitro digestion, although the 399 
bioaccessibility of TPC was greatest in the rye bread (62%), the net PA content was greatest in the 100% 400 
wheat bread (401 mg GAE/kg) with 58% bioaccessibility, followed by buckwheat (366 mg GAE/kg; 45%), 401 
rye (334 mg GAE/kg; 62%) and then oat (264 mg GAE/kg; 41%). The lower bioaccessibility in the 402 
buckwheat and oat breads may be due to their substantially greater fibre and protein contents in the 403 
respective flours (13.8% and 17.4%, and 18.9% and 21.5%, respectively) compared to the white wheat and 404 
rye breads (2.2% and 12.6%, and 14.6% and 9.6%, respectively). The higher fibre and protein content may 405 
partially prevent the digestive enzymes to free bound PAs, thus limiting their bioaccessibility. The same 406 
study also assessed blends of flours, specifically the multigrain bread “blend 15%” (oat:rye:buckwheat:wheat 407 
15:15:15:55, “blend 20%” (20:20:20:40) and “blend 25%” (25:25:25:25), where the TPC in the initial bread 408 
increased with the increase in wheat flour replacement (from 592 to 745 to 916 mg GAE/kg). Interestingly, 409 
the higher the substitution level of wheat flour by minor cereal and pseudocereal, the lower the percentage of 410 
TPC bioaccessibility, with the highest value (80%) reached with the 15% blend. However, the net TPC was 411 
comparable between the 3 blends (472, 549, 504mg GAE/kg corresponding to the 15, 20, 25% blends), and 412 
was actually greater than any of the 100% breads (401, 366, 334 and 264 mg GAE/kg, for wheat, buckwheat, 413 
rye and oat breads, respectively). Therefore, there may be some influential effect on PA bioaccessibility 414 
resulting from mixed grains, regardless of the actual quantities of each individual type. Comparing the 100% 415 
wheat flour bread with the 15% blend, which was 55% wheat flour, it is interesting to notice that that the 416 
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initial TPC content of the 100% wheat flour bread was higher (685 vs. 592mg GAE/kg TPC), yet the final 417 
bread TPC is higher in the 15% blend (472 vs. 401mg GAE/kg).  418 
In another study by the same authors, a 40% barley bread (made by replacing 40% wheat flour with barley 419 
flour) showed no difference in net TPC (597 vs. 598 mg/100g, respectively) and a much lower % 420 
bioaccessibility (60% vs. 84%, respectively, although the difference in TPC in the flour was higher (1003 421 
mg/100g vs. 713 mg/100g)78. Perhaps the specific barley flour used, commercial barley flour, had low 422 
bioaccessibility due to greater fibre content (4.01 vs. 1.15 g/100g, in the respective breads). When the type of 423 
barley flour was changed to a high β-glucan barley flour, the percentage bioaccessibility was still lower 424 
compared to the bread made from refined common wheat flour (42% vs. ~84%, respectively), again likely 425 
due to the higher fibre content (11.91 vs. 1.15 g/100g in the respective breads). However, the net TPC was 426 
much greater in the high β-glucan barley bread compared to the 100% white wheat bread (857 vs. 598 427 
mg/100g, respectively) because the TPC in the raw flour was ~3-fold higher (2197 vs. 713 mg/100g, 428 
respectively). Beta-glucan is a soluble, viscous-type fibre, which may therefore contribute to the low PA 429 
bioaccessibility since β-glucans can produce viscous gels able to entrap nutrients and phytochemicals, 430 
including phenolics, as previously hypothesized72. This may also explain part of the particularly lower 431 
bioaccessibility in the oat bread found in the study discussed above72, since oats are also a rich source of β-432 
glucan soluble fibre. Overall, these studies demonstrate that the types of grain flour used in blends may be 433 
influential on PA bioaccessibility. 434 
Another way to increase PA content in breads by modifications of raw materials includes the addition of 435 
selected fractions from the original grain. One of the most commonly used fractions is the cereal bran, as it is 436 
a recognized source of phenolics, including PAs. Mateo Anson et al. (2009b)84 compared a wholemeal bread 437 
to a wholemeal bread added with native wheat bran. Although they found the same FA bioaccessibility in 438 
both breads (1.1%), the net FA content in the wholemeal bread plus bran was greater, since the bread plus 439 
bran had a greater initial content of FA (1300 µg/g vs. 800 µg/g). The potential reason why the FA 440 
bioaccessibility was the same between the breads is because the bioaccessibility of FA is mainly associated 441 
with the amount of free FA present in breads, and the FA in the bran is mostly bound. Mateo Anson et al. 442 
(2009b)84 demonstrated a strong correlation between the amount of free FA and bioaccessibility among five 443 
breads. This hypothesis is further supported by the study of Koistinen et al. (2017)76, where the authors 444 
Page 18 of 47Food & Function
17 
 
compared wheat bread made with bioprocessed rye bran to the same bread made with native rye bran and 445 
found that FA bioaccessibility was significantly greater in the bread with the bioprocessed rye bran (88% vs. 446 
51%, respectively). This was also reflected in the bioaccessibility of total PAs (89% vs. 53%, respectively). 447 
The bioaccessibility was not directly calculated in this study. However, by calculating it as the difference 448 
between polyphenol content in the original sample and the residue of the enzymatic digestion86, percentage 449 
bioaccessibility of PAs was inferred.  450 
In addition to the use of bran, bread can be enriched with the polyphenol-rich aleurone fraction, as was 451 
investigated in two studies69,74. In the study by Mateo Anson et al. (2009a)69, the addition of aleurone 452 
resulted in a substantial increase in initial FA in the bread compared to the white bread (2290 µg/g and 33.5 453 
µg/g, respectively). After in vitro dynamic digestion, an increase in FA bioaccessibility was detected in the 454 
aleurone-enriched bread (0.57%) compared to white bread (not detected). Furthermore, Mateo Anson et al. 455 
(2009a)69 demonstrated that the aleurone-enriched bread had a level of FA bioaccessibility that was ∼60% 456 
lower than that found in a raw flour which had free FAs added (which was used as a “positive” control). In 457 
the aleurone-enriched bread, the majority of FA was present in bound form and only 20 µg/g as free FAs. 458 
Considering that only free and conjugated phenolic compounds are readily available for absorption, these 459 
results further support the consideration that free phenolic compounds are the major contributors to the 460 
bioaccessibility of PAs. Conversely, bound phenolics, being largely attached to undigested cell wall 461 
polysaccharides, are mainly retained into the material reaching the colon.  462 
The static model study by Dall’Asta et al. (2016)74 showed instead that aleurone-enriched bread resulted in 463 
bioaccessibility values 2.5-fold to 4.4-fold greater compared to whole grain bread for various PAs, including 464 
a 3-fold greater bioaccessibility for FA. These results are particularly interesting, since the aleurone bread 465 
had approximately half the amount of PAs compared to the wholegrain bread (total FA 70.67 vs. 144.78 466 
mg/100g, respectively). Although the results from this latter study contrast the ones of Mateo Anson et al. 467 
(2009a)69, they are supported by a previous study where it was reported that, in addition to the free form, a 468 
relevant percentage of the bound fraction may become available for absorption following digestion87. The 469 
mechanisms through which aleurone additions may influence PA bioaccessibility in the two studies may be 470 
ascribable to several factors. In addition to the differences between the in vitro method used (TIM versus 471 
static), the studies differed in the applied digestion length (6 versus 24 hours), in the aleurone content (22% 472 
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vs. 9.3% aleurone flour in the final dough), and in the kind of phenolic compounds considered (i.e. the 473 
consideration of di- and tri-FA in the work of Dall’Asta et al. (2016)74). Regardless, both studies demonstrate 474 
that the use of the polyphenol-rich aleurone fraction may represent a valuable source of phenolics and as an 475 
attractive strategy for producing breads with bioaccessible PAs, along with the advantage of more acceptable 476 
sensory characteristics. 477 
In vitro bioaccessibility studies investigating effects of pre-processing techniques in bread-making on 478 
polyphenolic content  479 
Beyond using different raw materials to influence PA content, innovative technologies have been developed, 480 
including pre-processing techniques, with the aim to improve the release of bound phenolic compounds and 481 
thus their bioaccessibility. Biotechnological processing and dry-fractionation of wheat bran are two types of 482 
technologies that have thus far been investigated in in vitro digestion studies assessing bioaccessibility of 483 
phenolic compounds in bread76,83,84.  484 
Fermentation and enzymatic treatment are two biotechnological processing techniques applied during bread-485 
making, which have been investigated on their effect on the bioaccessibility of FA, CA and SA. One study 486 
compared a wholemeal bread with native wheat bran to one where the wheat bran had been fermented and to 487 
another where the wheat bran had been both fermented and enzymatically treated with xylanase, β-488 
glucanase, α-amylase, cellulase and ferulic acid esterase84. All three breads had the same initial content of 489 
FA, CA and SA. However, after a dynamic digestion method was applied, the bioaccessibility of FA was 490 
twice as high in the bread with fermented wheat bran and 5-fold higher in the bread with fermented and 491 
enzymatically treated wheat bran, compared to the bread with native wheat bran. A slightly smaller but 492 
similar trend was observed for CA and SA. The great increase in bioaccessibility in the bread with 493 
bioprocessed bran may be due to the hydrolysis of different wheat fibre polymers resulting from to the 494 
hydrolytic enzymes, which may lead to a structural breakdown of bran cell walls. 495 
Mandak and Nystrom (2013)77 also evaluated the effect of enzymatic treatment, and assessed the 496 
bioaccessibility of steryl ferulates, which are phytosterols that can be esterified to FA, in breads made with 497 
two types of wheat flour, either with or without the use of the enzymes cellulose or xylanase, alone or in 498 
combination. The bioaccessibility of steryl ferulate (calculated as the percentage in the supernatant compared 499 
to the total extractable amount) was generally very low (0.01-0.25%), although when both enzymes were 500 
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used, bioaccessibility increased from 0.01 to 0.25% in wholegrain breads, but only from 0.09 to 0.10% in 501 
baking flour breads. The differences in effect of enzymatic treatment seen in this study versus the study by 502 
Mateo Anson et al. (2009b)84 may be: i) the specificity in the phenolic compounds assessed (steryl ferulates 503 
vs. PAs); ii) the specific enzymes used and the number and combination of them (xylanase and cellulase vs. 504 
β-glucanase, xylanase, α-amylase and ferulic acid esterase); iii) the method of bread preparation (direct 505 
incorporation of the enzymes to the flour vs. preliminary bioprocessing of bran); and iv) the digestion 506 
method employed (static vs. dynamic).  507 
As previously mentioned, Koistinen et al. (2017)76 recently investigated the bioaccessibility of phenolic 508 
compounds in a bioprocessed (by enzymatic treatment and fermentation) rye bran added to wheat bread, and 509 
found a stunning 88% bioaccessibility of FAs. Bioaccessibility was therefore much higher than that of the 510 
two previous studies, possibly because a considerable amount of phenolic bound compounds became 511 
available due to the addition of enzymes and the activation of endogenous enzymes resulting from 512 
fermentation. 513 
The bioaccessibility of PAs in bread was also increased when wheat bran was dry-fractionated. Hemery et al. 514 
(2010)83 analysed free, conjugated, bound and total FA, SA and CA in bread made following bran ultra-fine 515 
grinding and bran electrostatic separation. They found that the finer the bran particles in bran-rich breads, the 516 
more bioaccessible the PAs (following Tiny-TIM digestion), with a very strong correlation between FA 517 
bioaccessibility and the proportion of small particles (10-20 µm diameter). The bioaccessibility of SA was 518 
generally much higher than that of CA or FA (26-33% versus 6-13% and 2.5-3.4%), likely because SA is 519 
mainly present in the conjugated form and within the aleurone grains88. Furthermore, although the breaking 520 
of covalent bonds during extensive milling contributes to increased bioaccessibility89, the particle size of the 521 
samples seems to play a role in determining the bioaccessibility of phenolic compounds, possibly through an 522 
improvement of the extractability resulting from micronization90. The described study also found SA 523 
bioaccessibility was highly correlated to the proportion of small particles (<10um diameter), and the authors 524 
furthermore evaluated also bread made with positive and negative fractions obtained by electrostatic 525 
separation of bran, after the highest level of grinding (cryo-ultrafine), and demonstrated these to have the 526 
highest amount of bioaccessible PAs. The charge of these particles was influenced by the type of cell walls 527 
(branched and cross-linked vs. linear oligosaccharides), with separation between fibre-rich particles of 528 
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pericarp (outer cell wall), rich in highly branched and cross-linked arabinoxylans (negatively charged) and 529 
particles rich in β-glucan, FA and CA from aleurone cell walls (positively charged)91. These results provide 530 
insights for the improvement of electrostatic separation processes able to select specific fractions rich in free 531 
and conjugated PAs40. 532 
Overall, the studies investigating the bioaccessibility of phenolic compounds in bread suggest alterations, 533 
such as the incorporation of polyphenol-rich raw materials and, especially, the application of different bio-534 
processing techniques represent promising strategies to increase the amount of bioaccessible phenolic 535 
compounds in bread. The significant variations among the in vitro methods used impede a proper 536 
comparison of the results across studies and make the possibility to deduce general findings very difficult. To 537 
circumvent this, Minekus et al. 201492 recently published an international consensus paper aimed at 538 
introducing a standardised in vitro digestion method to analyse food, providing recommendations for every 539 
step of digestion. Adoption of this standardized method will assist in comparison of multiple study results in 540 
the future, allowing for clearer conclusions to be drawn. 541 
 542 
BIOAVAILABILITY OF PHENOLIC COMPOUNDS IN BREAD: in vivo studies 543 
Determining the content of bioactive compounds in food products or their sole bioaccessibility in vitro is not 544 
sufficient per se to predict their potential health effects in vivo. Therefore, in vivo studies are important to 545 
determine the bioavailability of PAs in order to understand the amount of PA actually absorbed post-546 
ingestion, becoming therefore available to elicit health effects. 547 
A review of the literature identified 5 studies investigating the bioavailability of PAs from standard versus 548 
bioprocessed bread (Table 3). The most common methodology used in vivo to assess phenolic bioavailability 549 
is represented by acute studies, where subjects are provided a single-dose of the test food and biological 550 
samples (e.g. blood, urine) are collected pre- and post-consumption. The changes, therefore, reflect the 551 
ability to absorb polyphenols from a complex food matrix93. Three out of the five identified studies were 552 
single-dose acute studies, with 2 evaluating the bioavailability of phenolics in bread in urine and plasma49,94 553 
and 1 in urine alone95.  554 
Bioavailability was calculated in all studies as the ratio between the amount of the excreted phenolic 555 
compounds and the amount provided with in the fed bread sample. Bresciani et al. (2016)94 specifically 556 
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detected and quantified secondary metabolites of phenolic compounds and described the bioavailability as 557 
the sum of these conjugated metabolites, while Lappi et al. (2013)95 and Mateo Anson et al. (2011)49 558 
performed an enzymatic hydrolysis of the urinary sample by using a mixture of β-glucuronidase and 559 
sulfatase from Helix pomatia. This reaction allows to cleave the glucuronic and sulfonic moieties of the 560 
phase II metabolites and to detect the only aglycones, to which the bioavailability is accounted for. 561 
As discussed, raw materials as well as bioprocessing techniques in bread-making play important roles in the 562 
bioavailability of phenolic compounds in breads. Product innovation in these acute studies was based on 563 
three main strategies: i) the addition of aleurone fraction to commercial wheat breads94; ii) bioprocessing of 564 
wheat bran added to a whole grain bread49; and iii) the use of rye bread and rye bran95.  565 
All 3 acute studies evaluated the urinary bioavailability of FA. Bresciani et al. (2016)94 fed healthy 566 
volunteers, on three separate days, a wholegrain bread and a 6% w/w aleurone-enriched bread at two 567 
different servings of 94 g and 190 g, containing 43 mg and 87 mg total FA, respectively. Results showed a 568 
significant 2-fold higher FA bioavailability (as the sum of FA metabolites ferulic acid-4’-O-sulfate, 569 
dihydroferulic acid-4’-O-sulfate, and dihydroferulic acid-O-glucuronide) in urine of volunteers fed with the 570 
single portion of the aleurone-enriched bread compared to wholegrain bread and to the double portion of 571 
aleurone-enriched bread. Intriguingly, no significant difference was found in urinary FA bioavailability 572 
between the double portion of aleurone-enriched and wholegrain breads (~5% and ~4%, respectively). The 573 
authors commented that the higher bioavailability derived from the lower ferulic consumption in the single 574 
compared to double portion of aleurone-enriched bread may be due by a reduction in the capacity to 575 
metabolize and absorb PAs as intake increases.  576 
Mateo Anson et al. (2011)49 demonstrated similar results when breads were standardized to contain the same 577 
initial total PA amount. Specifically, they found 10% FA bioavailability in the bread with bioprocessed bran 578 
compared to 4% in the whole wheat control bread with native bran (21.34 mg/24h vs. 9.89 mg/24h FA in 579 
urine, p < 0.05). Furthermore, Lappi et al. (2013)95 found a 2.5-fold greater urinary FA excretion after 580 
consumption of whole wheat bread with bioprocessed rye bran compared to the same whole wheat bread 581 
with native rye bran and with control wheat. For a thorough comprehension of the results of this study, it is 582 
important to consider the initial amount of FA in the fed bread. Indeed, the control wheat bread in this study 583 
showed a 3.2% FA bioavailability, as per excretion in urine, even if the initial FA intake was much lower 584 
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compared to both the rye or the bioprocessed rye brans. Thus, the total FA urinary excretion was lower (0.27 585 
mg/d in control whole wheat bread vs. 1.66 mg/d from bioprocessed rye bran bread vs. 0.45 mg/d in native 586 
rye bran bread, corresponding to 3.2%, 1% and 0.4% FA bioavailability, respectively). Therefore, although 587 
the percentage bioavailability may be higher, if the initial intake is lower, the total amount absorbed may 588 
nevertheless be lower. 589 
The application of bioprocessing techniques to breads, similarly, elicited increased bioavailability for SA and 590 
other PAs. The study by Mateo Anson and colleagues (2011)49 found that the amount of SA in 24-hour urine 591 
corresponded to a 15% and 7% bioavailability in bioprocessed bran and control breads, respectively. 592 
However, the bioavailability for CA equalled 2% for both the bioprocessed and control breads. Lappi et al. 593 
(2013)95 showed a 0.6% SA bioavailability for the bioprocessed bread compared to a 2.8% for white wheat 594 
bread, and generally all three breads were characterised by a ~4-fold lower SA bioavailability compared to 595 
the white wheat bread. In spite of this, the bioprocessed bread showed the highest excreted SA net amount 596 
(0.23 mg vs. 0.06-0.12 mg in the other three breads). Similar results were found for CA bioavailability. 597 
Intriguingly, Mateo Anson et al. (2011)49 evaluated the percentage vanillic acid bioavailability based on 24-598 
hour urine excretion and demonstrated 160% and 104% bioavailability in the bioprocessed and control 599 
breads, respectively, and both had similar initial concentrations in breads (0.018 mg/g and 0.017 mg/g, 600 
respectively), thus the bioprocessed bran bread resulted in greater vanillic acid absorption. Authors did not 601 
provide a possible explanation for such high recoveries, which could be at least partially attributable to an 602 
insufficient initial extraction of phenolics from the bread.  603 
Two studies also evaluated blood concentrations of phenolic compounds after bread consumption49,94 and 604 
both demonstrated increased hippuric and hydroxyhippuric acid plasma levels after bread consumption. 605 
However, being degradation products from several different metabolic pathways, these two catabolites 606 
cannot be considered uniquely associated to polyphenol metabolism22. The second most concentrated 607 
polyphenol compound in plasma was FA, together with its main phase II conjugates. Bresciani et al. (2016)94 608 
found concentrations of the main FA metabolites (ferulic acid- 4’-O-sulfate and dihydroferulic acid-4’-O-609 
sulfate) ranging from 66 to 100 nmol/L at 90 minutes after bread intake, with no significant differences 610 
among the various breads. Mateo Anson et al. (2011)49, however, found a significantly higher plasma FA 611 
concentration from bioprocessed bread (2.7 µmol/L) compared to control bread (0.9 µmol/L). The contrast of 612 
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these results may be explained by the different initial intakes of FA, as, although the concentration of FA in 613 
breads were similar, in the latter study49 the subjects consumed 3 times as much bread (300 g vs. 94 g) and 614 
thus had a 3-fold higher FA intake. Two studies investigated the consumption of rye bran breads in the 615 
context of a dietary intervention. The study by Harder et al. (2004)96 compared 250 g/d of rye bran-enriched 616 
products with 250 g/d of control wheat products (Vitacell®) consumed for 6 weeks in a randomized, 617 
crossover designed intervention with a 4-week washout in 18 healthy postmenopausal women. Juntunen et 618 
al. (2000)97 similarly compared the consumption of 4-5 slices/d of rye bread with wheat bread for 4 weeks in 619 
a randomized, crossover design with a 4-week washout in 43 healthy volunteers (Table 3). Although it was 620 
not possible to calculate the bioavailability of phenolic compounds in the breads because measurements 621 
would have had to include phenolics found in foods consumed during the rest of the daily diet, 622 
measurements of phenolic metabolites in blood (plasma) and urine samples were compared after 623 
consumption of the different bread interventions. Moreover, in the study by Harder et al. (2004)96, in 624 
addition to rye bread, the authors also included rye-enriched muffins and crisp bread products, thus making 625 
the FA amount found in biological samples not originating solely from bread. These authors measured FA 626 
concentration in 48-hour urine collections and found urinary FA excretion was ~2 mg/24hour for the habitual 627 
diet (i.e. at baseline) and at the end of 6-weeks after the incorporation of white wheat bread (Vitacell®). 628 
However, at the end of 6-weeks of the intervention with rye bran-enriched bread products, FA excretion was 629 
2.5-fold higher (p< 0.05) compared with both the control wheat bread intervention (40.2% higher, p= 0.001) 630 
and the baseline diet (39.8% higher, p= 0.002). Considering the 10.2 mg FA/day intake during the rye bran 631 
intervention, the study demonstrated a recovery of 28% of FA metabolites. 632 
Juntunen et al. (2000)97 considered the plant lignans, secoisolariciresinol (SECO) and matairesinol (MAT), 633 
which are found in large quantities in rye cereal-based products and bio-transformed by gut microbiota into 634 
enterodiol and enterolactone (ENL), respectively, and the latter finally oxidized to ENL. After a 4-week 635 
dietary intervention on either wheat or rye bread consumption, total ENL excretion in 24-hour urine samples 636 
almost doubled after rye bread consumption (6.8 µmol/day for men and 7.8 µmol/day for women) compared 637 
to the period with wheat control bread (4.0 µmol/day for men and 3.7 µmol/day for women). However, 24-638 
hour urine ENL concentration at the end of the rye intervention was not significantly different from the 639 
baseline. Furthermore, there was no correlation between the intake of rye bread or plant lignans and ENL 640 
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urinary excretion, which is interesting considering the intake of rye bread was more than double during the 641 
rye bread intervention compared to the habitual diet. Additionally, no difference in serum ENL 642 
concentrations between pre- and post-rye intervention was observed and again, there was no correlation 643 
between rye intake and serum ENL concentration. It is possible that a plateau of ENL is physiologically 644 
reached independently from the intake of rye bread.  645 
CONCLUSIONS AND REMARKS 646 
Phenolic compounds are recognized for several beneficial effects on human health. These effects depend not 647 
only on their content in food products but also on their ability to be absorbed and become available within 648 
the human body. For this reason, in vitro and in vivo studies have been performed with the aim of 649 
investigating the bioaccessibility and bioavailability of phenolic compounds, respectively, suggesting that the 650 
use of specific raw materials (e.g. cereals/pseudocereals as alternatives to wheat, or specific cereal fractions) 651 
or of pre-processing techniques might represent valuable strategies for enhancing the phenolic content in the 652 
raw materials and for increasing the amount of bioaccessible and bioavailable compounds.  653 
Unequivocal conclusions could not be drawn at present, as the available studies widely differ for fed 654 
amounts of phenolic compounds and, more importantly, for the methodologies applied. This highlights a 655 
great need for standardization of methodologies used in in vitro studies in order to be able to compare results 656 
and draw conclusions on the potential usefulness of the application of innovative techniques to improve 657 
phenolic bioaccessibility. The few in vivo studies identified also highlight the need for further research to be 658 
carried out in this area to assess the effectiveness of the application of new strategies in the bread-making 659 
process on phenolic bioavailability. With the ultimate goal of eliciting health benefits, intervention trials will 660 
be required to assess if strategies that demonstrate effectiveness at increasing phenolics bioavailability 661 
translate then to improvements in health outcomes in humans. 662 
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Table. 1 Potential strategies to increase bioaccessibility and bioavailability of phenolic compounds in bread 
STRATEGY REASON/MECHANISM References 
Raw materials 
Type of 
grain/cereal 
Whole grains 
Keeping all the anatomic parts of the kernel, 
where phenolic compounds are located 
Hemery et al. (2007)40 
Rye, Barley 
Raw material naturally rich in phenolic 
compounds 
Dykes and Rooney (2007)98 
Minor cereals Taylor and  Duodu (2015)32 
Pseudocereals Alvarez-Jubete et al. (2010a)67 
Ancient grains Abdel-Aal and Rabalski (2008)
36 
Pigmented grains 
Abdel-Aal et al. (2012)
33 
Abdel-Aal et al. (2016)34 
Yu and Beta (2015)
35 
Selected fractions 
Bran Anatomic parts of the kernel, rich in phenolic 
compounds  
Rosa-Sibakov et al. (2015)99 
Aleurone layer 
Pre-processing 
Fractionation De-branning Selection of phenolic-rich fractions 
Blandino et al. (2013)41 
Martini et al. (2015)
43 
Zanoletti et al. (2017)
42 
Physical 
treatment 
Air classification Selection of phenolic-rich layers Verardo et al. (2011)
44 
Mechanical 
treatment 
Micronization 
Ultrafine grinding which damages the fiber 
matrix and increases the phenolic compounds 
available for extraction 
Zhu et al. (2010)
45 
Bio-technological 
 processes 
Germination 
Metabolic changes and/or increase in 
extractability by the activation of endogenous 
enzymes which break the bonds of bound 
phenolic compounds 
Hubner and Arendt (2013)46 
Alvarez-Jubete et al. (2010b)67 
Fermentation/leavening 
Release of insoluble bound phenolic 
compounds by activity of exogenous enzymes 
Katina et al. (2007)47 
Zhang et al. (2014)
48 
Poutanen et al. (2009)
100
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 Enzymatic treatment 
Addition of enzymes which act to increase free 
phenolic compounds available for extraction 
Sørensen et al. (2003)
52
 
Moore et al. (2006)53 
Bread-making 
process 
Mixing and kneading 
Release of bound phenolic compounds into 
free forms by mechanical action and/or 
activation of  oxygenase and peroxidase 
Hilhorst et al. (1999)62 
Abdel-Aal and Rabalski (2013)58 
Fermentation/ 
Leavening 
Length of fermentation 
Prolonged fermentation time increase the 
phenolic compounds available for extraction 
Yu and Beta (2015)
35
 
Type of fermentation  
(sourdough vs dry yeast) 
Increase in the release of insoluble bound 
phenolic compounds during sourdough 
fermentation favoured by the lowering of pH 
Boskov Hansen et al. (2002)
50 
Konopka et al. (2014)51 
Baking 
Temperature 
Possible decrease in phenolic content due to 
degradation (thermal labile) 
 
Possible increase in phenolic bioaccessibility 
due to the release resulting from intense heat 
E.g. The upper crust, exposed to the greatest 
heat, generally has the highest level of 
phenolic compounds 
Vogrincic et al. (2010)66 
Alvarez-Jubete et al. (2010)
67
 
 
Lu et al. (2014)59 
Gélinas and McKinnon (2006)
68
 
You and Beta (2015)
35
 
Maillard Reactions 
May result in newly generated phenolic 
compounds 
Gelinas and McKinnon (2006)
68
 
Michalska et al. (2008)71 
Time No known effect Gélinas and McKinnon (2006)
68
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Table 2: Summary of in vitro studies investigating the bioaccessibility of PAs resulting from the alterations to the bread-making process 
Reference 
(Method) 
Type of 
grain 
Type of bread 
Phenols 
analyzed 
Initial phenolic contentⱡ Main findings 
Total Free Net Content % bioaccessibility 
Mateo Anson et 
al. (2009)
69
 
 
(Dynamic- TIM) 
Wheat 
 
 
 
a) White bread 
b) Aleurone-enriched bread 
(50% flour replacement; 
22% in final dough) 
- FA µg/g FA 
  
a)  33.5  
b) 2290 
µg/g FA 
 
a) 2.4 
b) 20 
 
 
a) not detectable 
b) 0.69 mg free  
 
 
a) not detectable 
b) 0.57% free  
Angioloni and 
Collar (2011)72 
(Static) 
Wheat, oat, 
rye, 
buckwheat 
 
 
 
a) White wheat bread 
b) Buckwheat bread 
c) Rye bread 
d) Oat bread 
e) Blend 15%, Multigrain 
bread (oat:rye:buckwheat: 
wheat 15:15:15:55):  
f) Blend 20%, Multigrain 
bread (oat:rye:buckwheat: 
wheat 20:20:20:40):  
g) Blend 25%, Multigrain 
bread (oat:rye:buckwheat: 
wheat 25:25:25:25) 
- TPC mg GAE/kg  
 
a)  685  
b) 808  
c) 536  
d) 643  
e) 592  
 
 
 
f) 745 
 
 
 
g) 916 
n/a GAE mg/kg 
  
a) 401  
b) 366  
c) 334  
d) 264  
e) 472  
 
 
 
f) 549  
 
 
 
g) 504  
 
 
a) 58% 
b) 45% 
c) 62% 
d) 41% 
e) 80% 
 
 
 
f) 74% 
 
 
 
g) 55% 
Collar and 
Angioloni 
(2014)
78
 
(Static) 
Wheat, barley  
 
 
a) White wheat bread  
b) 40% barley bread (40% 
wheat replaced with 
commercial barley flour) 
c) 40% high beta-glucan 
barley bread (40% wheat 
replaced with high β-glucan 
barley flour) 
- TPC mg/100g dw in 
flour  
  
a) 713 
b) 1003 
 
 
c) 2197 
n/a mg/100g bread 
as is 
 
 
a) 598  
b) 597  
 
 
c) 857  
 
 
 
a) ~84%* 
b) ~60%* 
 
 
c) 42%* 
 
*based on initial 
content in flours 
Szawara-Nowak 
et al. (2016)75 
(Static) 
Wheat, 
buckwheat 
 
a) White wheat bread  
b) Dark wheat bread 
c) White wheat bread with 
white buckwheat flour 
- TPC  
a) 0.38 mg 
rutin eq./g dw 
b) 1.8 mg rutin 
eq./g dw 
n/a Soluble fraction: 
a) ∼9 mg 
rutin eq./g dw  
b) ∼9 mg 
rutin eq./g dw  
(Extrapolated) 
a) ∼20 folds  
 
b) ∼5 folds  
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(substitution from 10% to 
50%)   
d) White wheat bread with 
white roasted buckwheat 
groats (substitution from 
10% to 50%) 
e) Dark wheat bread with 
white buckwheat flour 
(substitution from 10% to 
50%)   
f) Dark wheat bread with 
white roasted buckwheat 
groats (substitution from 
10% to 50%) 
 
 
 
c) ∼8-fold 
increase with 50% 
substitution 
as compared to a) 
d) ∼11-fold 
increase with 50% 
substitution 
as compared to a) 
e) f) increase from 
1.5 to 3 times as 
compared 
to b) 
c) up to ∼11 mg 
rutin eq./g dw 
(50% 
substitution) 
d) up to ∼12.5 
mg 
rutin eq./g dw 
(50% 
substitution) 
e) up to ∼10.5 
mg 
rutin eq./g dw 
(50% 
substitution) 
f) up to ∼10.5 
mg 
rutin eq./g dw 
(50% 
substitution) 
c) ∼3.5 to ∼6 folds  
 
d) ∼3 to ∼5 folds  
 
e) ∼3 to ∼6 folds  
 
f) ∼2.5 to ∼4.5 
folds 
Dall’Asta et al. 
(2016)
74 
(Static)  
Wheat   
 
a) Whole grain bread 
(commercial) 
 
 
b) Aleurone-enriched bread 
(commercial) 
- FA 
- CA 
- SA 
- CFA 
mg/100g dw 
 
a) 144.78 FA 
         1.51 CA 
         3.08 SA 
        0.83 CFA 
b) 70.67 FA     
      0.87 CA 
      3.96 SA 
      0.28 CFA 
 
mg/100g dw 
 
a) 0.71 FA 
    0.02 CA 
    ND  SA 
   0.04 CFA 
b) 0.41 FA 
    0.05 CA 
    0.12 SA 
    0.02 CFA 
mg/100g dw 
(calculated) 
a) 18.97 FA 
   0.15 CA 
   0.99 SA 
   0.16 CFA 
b) 28.76 FA 
      0.26 CA 
      3.15 SA 
      0.23 CFA 
 
 
a) 13.1% FA 
   10.1% CA 
   32.2% SA 
   19.2% CFA 
b) 40.7% FA 
     29.5% CA 
     79.5% SA 
     83.3% CFA 
Mateo Anson et 
al. (2009)
84 
 
(Dynamic, TIM) 
Wheat  
a) White bread 
 
 
b) Whole-meal bread 
 
 
c) Whole-meal bread with 
native wheat bran 
 
d) Whole-meal bread with 
- FA 
- CA 
- SA 
µg/g dw 
  a) 86 FA 
   2 CA  
   9 SA  
 b) 810 FA 
  20 CA  
  70 SA 
c) 1300 FA 
  40 CA  
 130 SA 
d) 1300 FA  
µg/g free 
  a) 3.6 FA 
   0.8 CA 
   0.9 SA 
 b) 13 FA 
   0.9 CA 
   3.5 SA 
 c) 12 FA 
  1.2 CA 
  4.6 SA 
 d) 42 FA 
µg/g 
(calculated) 
a)   4.2 FA              
     n/a CA 
     n/a SA 
b)  8.91 FA              
      n/a CA 
      n/a SA 
c) 14.3 FA              
      2.08 CA 
      2.73 SA  
 
a) 4.9% FA  
n/a CA 
n/a SA  
b) 1.1% FA  
n/a CA 
n/a SA 
c) 1.1% FA  
5.2% CA 
2.1% SA 
d) 2.2% FA  
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fermented wheat bran 
e) Whole-meal bread with 
fermented and enzymatic 
treated bran 
   40 CA 
 130 SA 
e) 1300 FA  
  40 CA  
 130 SA 
 
  1.5 CA 
  9.6 SA 
e) 100 FA 
  3.0 CA 
  9.9 SA 
d) 28.6 FA              
      n/a CA 
      n/a SA  
e) 71.5 FA              
      3.96 CA 
      6.5 SA 
 
n/a CA 
n/a SA 
e) 5.5% FA  
9.9% CA 
5.0 % SA 
 
Hemery et al. 
(2010)
83
 
 
(Dynamic, Tiny-
TIM) 
Wheat  
a) White bread 
 
 
b) Whole bread (100% 
wheat grain) 
 
c) “Amb, medium”  
 
 
d) “Amb, fine” 
 
 
e) “Amb, ultrafine” 
 
 
f) “Cyro, ultrafine” 
 
 
g) “FES positive” 
 
 
h) “FES middle” 
 
 
i) “FES negative” 
 
* coarse bran increasingly 
processed from c-f; 
FES=cryo particles 
separated by charge; middle 
is mixed 
- FA 
- CA 
- SA 
 
µg/g dw 
a) 62.6 FA 
  2.5 CA 
  3.2 SA 
b) 793.2 FA 
 23.5 CA 
 40.7 SA 
c) 865.4 FA 
 24.7 CA 
 44.7 SA 
d) 898.5 FA 
 26.6 CA 
 41.0 SA 
e) 899.4 FA 
 26.8 CA 
 42.5 SA 
f) 869.8 FA 
 25.6 CA 
 44.2 SA 
g)1072.7 FA 
 30.9 CA 
 41.3 SA 
h)763.8 FA 
 22.0 CA 
 48.1 SA 
i) 625.8 FA 
 25.9 CA 
 38.1 SA 
µg/g dw 
 a) 1.2 FA 
 0.12 CA 
 0.09 SA 
b) 8.2 FA 
 0.28 CA 
 1.68 SA 
c) 12.4 FA 
 0.48 CA 
 1.17 SA 
d) 14.6 FA 
 0.55 CA 
 1.21 SA 
e) 15.6 FA 
 0.53 CA 
 1.17 SA 
f) 16.4 FA 
 0.56 CA 
 1.21 SA 
g) 12.4 FA 
 0.47 CA 
 1.36 SA 
h) 17.9 FA 
 0.65 CA 
 1.01 SA 
i) 15.5 FA 
 0.56 CA 
 1.28 SA 
µg/g dw 
a)   6.4 FA 
     0.87 CA 
     3.3 SA 
b) 22.7 FA 
     1.38 CA 
   18.1 SA 
c) 21.7 FA 
      1.49 CA 
    12.2 SA  
d) 26.2 FA 
      1.83 CA 
    13.8 SA 
e) 30.7 FA 
     2.47 CA 
   15.4 SA  
f) 26.7 FA 
     3.32 CA 
    11.7 SA  
g) 31.8 FA 
      3.59 CA 
      1.67 SA 
h) 23.0 FA 
      3.51 CA 
      9.8 SA 
i) 32.1 FA 
      3.93 CA 
    22.7 SA  
 
a) 10.2% FA  
    35% CA 
 102%  SA 
b)  2.9% FA 
     5.9% CA 
   45% SA 
c)  2.5% FA 
     6.0% CA 
   27% SA 
d) 2.9% FA 
    6.9% CA 
  33% SA 
e) 3.4% FA 
    9.2% CA 
  36% SA 
f) 3.1% FA 
  13% CA 
  25% SA 
g) 3.0% FA 
  12% CA 
  40% SA 
h) 3.0% FA 
  16% CA 
  20% SA 
i) 5.1% FA 
  15% CA 
  60% SA 
 
Mandak & Wheat  
a) Whole grain bread 
- Steryl ferulates 
(SF) 
µg/g dw SF 
a) 51.2  
n/a 
 
µg/g 
(calculated) 
 
a) 0.01% 
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Nystrom (2013)
77
 
(Static) 
b) Whole grain bread with 
xylanase 
c) Whole grain bread with 
cellulase 
d) Whole grain bread with 
xylanase and cellulase 
e) Baking flour based bread  
f) Baking flour based bread 
with xylanase  
g) Baking flour based bread 
with cellulase  
h) Baking flour based bread 
with xylanase and cellulase 
b) 53.0 
 
c) 52.7 
 
d) 52.1 
 
 
e) 21.7 
 
f) 18.3 
 
g) 19.6 
 
h) 17.0 
a) 0.005 
b) 0.016 
 
c) 0.016 
 
d) 0.130 
 
 
e) 0.020 
 
f) 0.004 
 
g) 0.010 
 
h) 0.017 
 
b) 0.03% 
 
c) 0.03% 
 
d) 0.25% 
 
 
e) 0.09% 
 
f) 0.02% 
 
g) 0.05% 
 
h) 0.10% 
 
Koistinen et al. 
(2017)
76
 
(Static) 
Wheat, rye  
a) Bread with  
native rye bran 
 
 
b) Bread with bioprocessed 
(enzymatic treatment and 
fermentation) rye bran 
- FA 
- CA 
- SA 
 
mg/g 
a) 1.082 FA 
0.037 CA 
0.242 SA 
 
b) 1.188 FA 
0.036 CA 
0.258 SA 
 
mg/g 
a) 0.016 FA 
0.001 CA 
0.008 SA 
 
b) 0.162 FA 
0.004 CA 
0.029 SA 
mg/g absorbed 
a) 0.549 FA            
    0.031 CA  
    0.146 SA             
     
b) 1.051
 
FA          
    0.034 CA  
   0.236 SA               
    
 
a)
 
 51% FA 
     84% CA  
    60% SA  
      
b) 
 
88% FA  
      94% CA  
    91%SA  
 
CA, p-coumaric acid; CAF: caffeic acid; FA, ferulic acid; GAE, gallic acid equivalents; PA, phenolic acid; SA, sinapic acid; TPC, total phenolic acid content; 
dw: dry weight. 
 
ⱡ as measured in the bread pre-digestion, unless otherwise indicated 
*
 % of bioaccessibility was calculated as the percentage of phenolic compounds in the residue after in vitro digestion compared to the initial amount of total 
PAs/TPC in bread  
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Table 3. Human studies investigating the bioavailability* and the recovery of bread-derived polyphenols  
 
Reference Test Samples Type of study Subjects Analysis Findings 
Single-dose dietary intervention 
Bresciani et 
al. (2016)94 
- WGB: 94 g of wholegrain 
bread, 0.926 mg/g total FA;  
- AB-94: 94 g of a commercial 
wheat bread enriched in 
aleurone fraction (6% w/w), 
0.458 mg/g total FA;  
- AB-190: 190 g of a 
commercial bread enriched 
in aleurone fraction (6% 
w/w), ∼ 0.458 mg/g total FA. 
Randomized, 
crossover, 
single-dose, 
single-blind, 
intervention, 
at least 1-
week washout 
period. 
15 healthy 
subjects, 
mean age 
26 ± 4 y, 
mean BMI 
21 ± 3 
kg/m
2
. 
- Plasma ferulic acid- 4’-
O-sulfate, 
dihydroferulic acid-4’-
O-sulfate: 0, 0.5, 1, 2, 
4, 7 and 24 h; 
- Urinary ferulic acid-4’-
O-sulfate, 
dihydroferulic acid-4’-
O-sulfate, and 
dihydroferulic acid-O- 
glucuronide, 
feruloylglycine, 
dihydrocaffeic acid 
sulfate, sinapic acid 
sulfate, vanillic acid-4-
O-sulfate and 
hydroxybenzoic acid 
sulfate : 0-3, 3-6, 6-10, 
10-14, 14-24, 24-28, 
28-34 and 34-48 h. 
 
 
Plasma phenolic acid metabolites: 
- Ferulic acid- 4’-O-sulfate Cmax  
- WGB 84.3 nM; 
- AB-94 55.5 nM; 
- AB-190 76.6 nM. 
- Dihydroferulic acid-4’-O-sulfate Cmax  
- WGB 9.2 nM; 
- AB-94 9.5 nM; 
- AB-190 11.9 nM. 
- No significantly differences in Cmax among the tested 
bread for ferulic acid- 4’-O-sulfate and dihydroferulic acid-
4’-O-sulfate. 
 
Urine metabolites: 
- Cumulative 48 h excretion 
- Dihydrocaffeic acid sulfate: 
- AB-94: ~2 µmol; 
- AB-190: ~2 µmol; 
- WGB: ~0.8 µmol. 
- Sinapic acid sulfate: 
- AB-94: ~2 µmol; 
- AB-190: ~1 µmol; 
- WGB: ~1 µmol. 
- Significantly higher (p< 0.05) cumulative 48 h excretion 
of  dihydrocaffeic acid sulfate in AB-94 and AB-190 
compared to WGB; no statistical differences between 
AB breads; 
- Significantly higher (p< 0.05) cumulative excretion of 
sinapic acid sulfate in AB-190 compared to AB-90 and 
WGB; no statistical differences between AB-90 and 
WGB breads. 
- % Bioavailability: 
- AB-94 +8%; 
- AB-190: +4%; 
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- WGB: +4%. 
- 2-fold higher (p< 0.05) bioavailability of the sum of FA 
in AB-94 compared to WGB and AB-190 WGB.  
- ~2-fold higher bioavailability of the sum of FA in AB-
190 compared to WGB (not significant). 
Lappi et al. 
(2013)95 
- R bread: 123g commercial 
wholegrain rye bread (100% 
rye flour), 0.602 mg/g FA; 
- WW bread: 109 g white 
wheat bread, 0.606 mg/g FA; 
- RB + WW bread: 164 g 
white wheat bread fortified 
with native rye bran (35% 
replacement), 0.713 mg/g 
FA;  
- BRB +WW bread: 166 g 
white wheat bread fortified 
with bioprocessed rye bran 
(35% replacement), 0.811 
mg/g FA; 
Randomized, 
cross-over, 
single-dose, 
intervention, 
at least 3-day 
washout 
period. 
15 healthy 
subjects, 
mean age 
57 y, mean 
BMI 26 
kg/m2. 
- Urinary FA, SA and PA 
equivalents: the 0–4, 4–
12, and 12–24 h. 
 
 
FA equivalents bioavailability:  
- BRB+WW: 1%; 
- RB+WW: 0.4%; 
- R: 0.4%;  
- WW: 3.2%. 
SA equivalent bioavailability:  
- BRB+WW: 0.6%; 
- RB+WW: 0.4%; 
- R: 0.3%;  
- WW: 2.8%. 
PA equivalent bioavailability:  
- BRB+WW: 0.3%; 
- RB+WW: 0.3%; 
- R: 0.3%, 0.07;  
- WW: 3.8%. 
 
Mateo 
Anson et al. 
(2011)49 
- Control Bread: 300 g whole 
wheat bread containing 
native bran, 0.767 mg/g FA, 
0.057 mg/g sinapic acid, 
0.018 mg/g p-coumaric acid, 
0.017 mg/g vanillic acid; 
- Bioprocessed bread: 300 g 
bioprocessed bran, 0.733 
mg/g FA, 0.057 mg/g, 
sinapic acid, 0.015 mg/g p-
coumaric acid, 0.018 mg/g 
vanillic acid; 
Randomized, 
single-blind, 
single dose,  
cross-over 
intervention, 
at least 1-
week washout 
period.  
 
 
8 healthy 
men, range 
age 21-55 y, 
range BMI 
20-30 kg/m
2
. 
- Plasma ferulic, vanillic 
and 3,4-
dimethoxybenzoic acids 
relative bioavailability 
(AUC0-t): 0.25, 0.5, 
0.75, 1, 1.25, 1.5, 2, 3, 
4, 5, 6, 9, 12 and 24 h. 
- Urinary FA, SA, CA, 
VA, and their 
secondary metabolites: 
0 and 24 h. 
 
Plasma metabolites: 
- FA relative bioavailability (AUC0-t): 
- Control Bread: 240 µmol*min/L; 
- Bioprocessed Bread: 640 µmol*min/L. 
- VA relative bioavailability (AUC0-t): 
- Control Bread: 39 µmol*min/L; 
- Bioprocessed Bread: 70 µmol*min/L. 
- 3,4-dimethoxybenzoic acid relative bioavailability (AUC0-
t): 
- Control Bread: 5.4 µmol*min/L 
- Bioprocessed Bread: 9.9 µmol*min/L 
- Significantly higher (p< 0.05) relative bioavailability 
(AUC0-t) of ferulic acid (2.7-fold),  vanillic and 3,4-
dimethoxybenzoic acid (1.8-fold each) from bioprocessed 
bread compared to the control bread. 
 
Urine metabolites: 
- % Recovery FA:  
- Control Bread: 4%; 
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- Bioprocessed Bread: 10%. 
- % Recovery SA:  
- Control Bread: 7%; 
- Bioprocessed Bread: 15%. 
- % Recovery CA:  
- Control Bread: 2%; 
- Bioprocessed Bread: 2%. 
- % Recovery VA:  
- Control Bread: 104%; 
- Bioprocessed Bread: 160%. 
- 2-fold significantly higher (p< 0.05) urinary 
bioavailability of FA, SA, VA, from bioprocessed bread 
compared to control bread.  
- No differences in urinary bioavailability of CA from the 
tested breads. 
Chronic dietary intervention 
Harder et al. 
(2004)
96 
- 250 g control wheat products 
(Vitacell
®
), 0 mg FA); 
 
- 250 g rye bran enriched 
products, 0.041 mg/g FA 
from rye bran 
 
- Both the categories included 
bread, muffin and crisp 
bread products. 
 
Randomized, 
crossover 
intervention, 
two 6-week 
interventions, 
4-week 
washout 
period. 
18 healthy 
postmenopa
usal 
women, 
mean age 
63.3±1.2 y, 
mean BMI 
25.1±0.9 
kg/m
2
 
- Urinary FA equivalents: 
0-48 h. 
- Urinary FA equivalents 24 h-excretion: 
- Baseline:1.92 mg;  
- Control wheat: 1.94 mg; 
- Rye Bran: 4.82 mg; 
- 1.5-fold higher urinary FA equivalents excretion from rye 
bran enriched products compared to the baseline (+39.8%, 
p= 0.002) and Vitacell® (+40.2%, p= 0.001); 
- Not significant difference in FA equivalents urinary 
excretion from Vitacell
® 
products compared to baseline 
(+1%). 
Juntunen et 
al. (2000)97 
- Wheat bread consumption 
(Lignans: 0.109 µg/g); 
- Rye bread consumption 
(Lignans, 0.888 µg/g). 
 
A minimum of 4-5 slices of 
bread consumption per day 
was required, no maximum 
intake indicated. 
Randomized, 
crossover, 2-
week run-in, 
two 4-week 
interventions, 
4-week wash-
out. 
 
43 healthy 
volunteers, 
mean age 
43±2 y, 
range BMI 
20-32 kg/m2 
- Serum ENL 
concentration: 0 and 4 
weeks; 
- 24 h urinary ENL 
excretion:0 and 4 
weeks.  
- 24 h urinary ENL 
concentration:0 and 4 
weeks. 
- Serum ENL concentration 
- Baseline: 
- Men: 28.1 nM; 
- Women:  39.3 nM. 
- Wheat bread: 
- Men: 12.5 nM; 
- Women:  14.8 nM. 
- Rye bread: 
- Men: 25.6 nM; 
- Women: 39.7 nM. 
- Significant higher serum ENL concentrations at the end 
of rye-brad intervention compared to wheat bread one 
(+51.2% for men, +62.7% for woman, p <0.05). 
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- Not significant differences in serum ENL concentration 
at the end of rye- and wheat-brad compared to baseline. 
 
- Urinary ENL 24 h-excretion 
- Wheat bread: 
- Men: 4.0 µmol; 
- Women:  3.7 µmol. 
- Rye bread: 
- Men: 6.8 µmol; 
- Women: 7.8 µmol. 
 
- Significantly higher (p< 0.05) ENL 24 h-excretion in 
rye- compared to wheat-bread periods in both men and 
women. 
- No correlation between urine ENL and  rye bread 
intake. 
 
AUC0-t: area under the curve; Cmax: maximum plasma concentration; CA, p-coumaric acid; ENL: enterolactones; FA, ferulic acid; SA, sinapic acid; VA, vanillic 
acid. 
 
* % of bioavailability was calculated as % ratio between the amount of the compound in the biological fluid on the amount of the ingested compound. 
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